- adj.
- 抗不安の
- n.
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/07/19 03:08:12」(JST)
wiki en
|
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
(Learn how and when to remove this template message)
|
An anxiolytic (also antipanic or antianxiety agent)[1] is a medication or other intervention that inhibits anxiety. This effect is in contrast to anxiogenic agents, which increase anxiety. Together these categories of psychoactive compounds or interventions may be referred to as anxiotropic compounds or agents. Some recreational drugs such as ethanol (alcohol) induce anxiolysis initially; however studies, show that many of these drugs are anxiogenic. Anxiolytic medications have been used for the treatment of anxiety and its related psychological and physical symptoms. Anxiolytics have been shown to be useful in the treatment of anxiety disorders. Light therapy and other interventions have also been found to have an anxiolytic effect.[2]
Beta-receptor blockers such as propranolol and oxprenolol, although not anxiolytics, can be used to combat the somatic symptoms of anxiety such as tachycardia and palpitations.[3]
Anxiolytics are also known as minor tranquilizers.[4] The term is less common in modern texts, and was originally derived from a dichotomy with major tranquilizers, also known as neuroleptics or antipsychotics.[citation needed]
There are concerns that some GABAergics, such as benzodiazepenes and barbituates, may have an anxiogenic effect if used over long periods of time.[5]
Contents
- 1 Medications
- 1.1 Barbiturates
- 1.2 Benzodiazepines
- 1.3 Carbamates
- 1.4 Opioids
- 1.5 Antidepressants
- 1.5.1 Selective serotonin reuptake inhibitors
- 1.5.2 Serotonin–norepinephrine reuptake inhibitors
- 1.5.3 Tricyclic antidepressants
- 1.5.4 Tetracyclic antidepressant
- 1.5.5 Monoamine oxidase inhibitors
- 1.6 Sympatholytics
- 1.6.1 Beta blockers
- 1.6.2 Alpha blockers
- 1.6.3 Alpha-adrenergic agonist
- 1.7 Miscellaneous
- 1.7.1 Mebicar
- 1.7.2 Fabomotizole
- 1.7.3 Selank
- 1.7.4 Bromantane
- 1.7.5 Emoxypine
- 1.7.6 Azapirones
- 1.7.7 Hydroxyzine
- 1.7.8 Pregabalin
- 1.7.9 Menthyl isovalerate
- 1.7.10 Cannabidiol
- 1.7.11 Tetrahydrocannabinol
- 1.7.12 Propofol
- 1.7.13 Racetams
- 1.8 Herbal treatments
- 1.9 Supplements and over-the-counter pharmaceutical drugs
- 1.10 Future drugs
- 1.11 Common drugs
- 1.11.1 Alcohol
- 1.11.2 Inhalants
- 2 Alternatives to medication
- 3 See also
- 4 References
Medications
Barbiturates
Main article: Barbiturate
Barbiturates exert an anxiolytic effect linked to the sedation they cause. The risk of abuse and addiction is high. Many experts consider these drugs obsolete for treating anxiety but valuable for the short-term treatment of severe insomnia, though only after benzodiazepines or non-benzodiazepines have failed.
Benzodiazepines
Main article: Benzodiazepine
Benzodiazepines are prescribed for short-term or episodic relief of severe and disabling anxiety. Benzodiazepines may also be indicated to cover the latent periods associated with the medications prescribed to treat an underlying anxiety disorder. They are used to treat a wide variety of conditions and symptoms and are usually a first choice when short-term CNS sedation is needed. Longer-term uses include treatment for severe anxiety. If benzodiazepines are discontinued rapidly after being taken daily for two or more weeks there is some risk of benzodiazepine withdrawal and rebound syndrome, which varies by the specific drug.[6] Tolerance and dependence may also occur, but may be clinically acceptable.[7] Cognitive and behavioral adverse effects are possible.[8] Benzodiazepines include:
- Alprazolam (Xanax)
- Bromazepam (Lectopam, Lexotan)
- Chlordiazepoxide (Librium)
- Clonazepam (Klonopin, Rivotril)
- Clorazepate (Tranxene)
- Diazepam (Valium)
- Flurazepam (Dalmane)
- Lorazepam (Ativan)
- Oxazepam (Serax, Serapax)
- Temazepam (Restoril)
- Triazolam (Halcion)
Benzodiazepines exert their anxiolytic properties at moderate dosage. At higher dosage hypnotic properties occur.[9]
- Tofisopam (Emandaxin and Grandaxin) is a drug that is a benzodiazepine derivative. Like other benzodiazepines, it possesses anxiolytic properties, but, unlike other benzodiazepines, it does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing, or amnestic properties.
Carbamates
Marketed as a safer alternative to barbiturate anxiolytics, meprobamate (Miltown, Equanil) was commonly used to relieve anxiety in the late 1950s and 1960s. Like barbiturates, therapeutic doses produce sedation and significant overdoses may be fatal. In the US, meprobamate has generally been replaced with benzodiazepines while the drug is now withdrawn in many European countries and Canada. The muscle relaxant carisoprodol has anxiolytic effects by metabolizing to meprobamate. Various other carbamates have been found to share these effects, such as tybamate and lorbamate.
Opioids
Opioids are drugs that are usually only prescribed for their painkilling properties, but some research is beginning to find that some varieties are effective at treating depression, obsessive compulsive disorder, and other ailments often associated with or caused by anxiety. They have a very high potential for abuse and have one of the highest addiction rates for all drugs. Many people become addicted to these drugs because they are so effective at blocking emotional pain, including anxiety. Similarly to alcohol, people with anxiety disorders are more likely to become addicted to opioids due to their anxiolytic effect. These drugs range from the commonly prescribed hydrocodone, to the notoriously illegal Diamorphine, and all the way to much more potent varieties like fentanyl often used in trauma or end of life pain management. Most people purchasing these drugs illegally are seeking them out to get a euphoric like high, but many others seek them out because they are so effective at reducing both physical pain and emotional pain.[10]
Because of their high potential for abuse and high overdose rates, prescribing opioids for mental health issues is very uncommon and frowned upon within the medical community. Safer opioids which are less likely to be abused, have less deadly drug interactions, and are less likely to cause overdose are the ones that are being looked into the most for their anxiolytic-type properties. Given that many anxiety sufferers are more prone to alcohol and opioid addiction, the potential danger in prescribing opioids is apparent. Benzodiazapenes are very similar to alcohol in how they impact the user and the brain, and even though anxiety sufferers are more prone to alcohol addiction these drugs are still prescribed. The same logic is being used in the push to get opioids used for anxiety treatment. Opioids and benzodiazapenes are very dangerous to use together, and using them together is one of the most common reasons for accidental mixed drug overdose in the United States, so great caution should be taken if opioid prescriptions for anxiety become more accepted.
It appears that buprenorphine is gaining some acceptability within in the medical community for being used to treat anxiety, OCD, and depression. Buprenorphine is similar to methadone in that it is used in opioid replacement therapy as well as pain management. It is much safer than methadone and lots of other opioids and has a very long half-life leading to less compulsive use among those who attempt to abuse it or become mentally addicted to it. There has been research into more commonly abused opioids being prescribed for anxiety disorder, but given that these drugs produce more euphoria and require more constant dosing when compared to buprenorphine, there is a much higher danger for abuse and overdose.[11]
Antidepressants
Antidepressant medications can reduce anxiety, and several selective serotonin reuptake inhibitors have been USFDA approved to treat various anxiety disorders. Antidepressants are especially beneficial because anxiety and depression often occur together.[6]
Selective serotonin reuptake inhibitors
Selective serotonin reuptake inhibitors or serotonin-specific reuptake inhibitors[12] (SSRIs) are a class of compounds typically used in the treatment of depression, anxiety disorders, OCD and some personality disorders. Primarily classified as antidepressants, most SSRIs have anxiolytic effects, although at higher dosages than used to treat depression. Paradoxically, SSRIs can increase anxiety initially due to negative feedback through the serotonergic autoreceptors. For this reason a concurrent benzodiazepine is sometimes used temporarily until the anxiolytic effect of the SSRI occurs.
Serotonin–norepinephrine reuptake inhibitors
Serotonin–norepinephrine reuptake inhibitor include venlafaxine and duloxetine drugs. Venlafaxine, in extended release form, and duloxetine, are indicated for the treatment of GAD. SSNRIs are as effective as SSRIs in the treatment of anxiety disorders.[13]
Tricyclic antidepressants
Tricyclic antidepressants (TCAs) have anxiolytic effects; however, side effects are often more troubling or severe and overdose is dangerous. Examples include imipramine, amitriptyline, nortriptyline and desipramine.
Tetracyclic antidepressant
Mirtazapine has demonstrated anxiolytic effects with a better side effect profile to all other classes of antidepressants, for example it rarely causes or exacerbates anxiety. However, in many countries (such as USA and Australia), it is not specifically approved for anxiety disorders and is used off label.
Monoamine oxidase inhibitors
Monoamine oxidase inhibitors (MAOIs) are effective for anxiety, but their dietary restrictions, side effects and availability of newer effective drugs, have limited their use.[6] First generation MAO inhibitors include: phenelzine, isocarboxazid and tranylcypromine. Moclobemide, a reversible MAO-A inhibitor, lacks the dietary restrictions associated with classic MAOI's, The drug is used in Canada, the UK and Australia.
Sympatholytics
Sympatholytics are a group of anti-hypertensives which inhibit activity of the sympathetic nervous system, and several medications medications within this group have shown anxiolytic effects as well as potential therapy for PTSD.
Beta blockers
Although not officially approved for this purpose, beta blockers also can have an antianxiety effect.[14][15]
Alpha blockers
The alpha1 antagonist prazosin could be effective for PTSD[16][17]
Alpha-adrenergic agonist
The Alpha2 adrenergic agonists Clonidine[18] and guanfacine has demonstrated both anxiolytic and anxiogenic effects.
Miscellaneous
Mebicar
Mebicar (mebicarum) is an anxiolytic produced in Latvia and used in Eastern Europe. Mebicar has an effect on the structure of limbic-reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity.[19] Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, and increases the brain serotonin level.[20]
Fabomotizole
Fabomotizole[21] (brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. Its mechanism of action remains poorly defined, with GABAergic, NGF and BDNF release promoting, MT1 receptor antagonism, MT3 receptor antagonism, and sigma agonism all thought to have some involvement.[22][23][24][25][26] It has yet to find clinical use outside of Russia.
Selank
Selank is an anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian academy of sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a synthetic analog of a human tetrapeptide tuftsin. As such, it mimics many of its effects. It has been shown to modulate the expression of interleukin-6 (IL-6) and affect the balance of T helper cell cytokines. There is evidence that it may also modulate the expression of brain-derived neurotropic factor in rats.[medical citation needed]
Bromantane
Bromantane is a stimulant drug with anxiolytic properties developed in Russia during the late 1980s, which acts mainly by inhibiting the reuptake of both dopamine and serotonin in the brain, although it also has anticholinergic effects at very high doses. Study results suggest that the combination of psychostimulant and anxiolytic actions in the spectrum of psychotropic activity of bromantane is effective in treating asthenic disorders compared to placebo.
Emoxypine
Emoxypine is an antioxidant that is also an anxiolytic. Its chemical structure resembles that of pyridoxine, a form of vitamin B6.
Azapirones
Azapirones are a class of 5-HT1A receptor agonists. Currently approved azapirones include buspirone (Buspar) and tandospirone (Sediel).
Hydroxyzine
Hydroxyzine (Atarax) is an antihistamine originally approved for clinical use by the FDA in 1956. In addition to its antihistamine properties hydroxyzine possesses anxiolytic properties and is approved for the treatment of anxiety and tension. Its sedative properties are useful as a premedication before anesthesia or to induce sedation after anesthesia.[27] Hydroxyzine has been shown to be as effective as benzodiazepines in the treatment of generalized anxiety disorder, while producing fewer side-effects.[28]
Pregabalin
Pregabalin's anxiolytic effect appears after one week of use and is similar in effectiveness to lorazepam, alprazolam, and venlafaxine, but has demonstrated more consistent therapeutic effects for psychic and somatic anxiety symptoms. Long-term trials have shown continued effectiveness without the development of tolerance, and unlike benzodiazepines, it does not disrupt sleep architecture and produces less severe cognitive and psychomotor impairment. Pregabalin also exhibits a lower potential for abuse and dependence than benzodiazepines.[29][30]
Menthyl isovalerate
Menthyl isovalerate is a flavoring food additive which is marketed as a sedative and anxiolytic drug in Russia under the name Validol. Sublingual administration of Validol produces a sedative effect, and has moderate reflex and vascular dilative action caused by stimulation of sensory nerve receptors of the oral mucosa followed by the release of endorphins. Validol is typically administered as needed for symptom relief.[31][32][33]
Cannabidiol
Cannabidiol (CBD) is a cannabinoid produced by Cannabis sativa and Cannabis indica, and in marginal quantities by Cannabis ruderalis. It is available in the United States in states where cannabis has been legalized for medical and general use. No lethal dose (or LD50) has been established from cannabidiol[citation needed]. In feral strains of cannabis, cannabidiol is produced in large quantities alongside the psychoactive cannabinoid tetrahydrocannabinol. Special strains of cannabis have been bred to yield high amounts of cannabidiol with significantly lowered synthesis of THC. Specific formulations for anxiety with a CBD to THC ratio of 18:1 are available in the US markets[citation needed].
Tetrahydrocannabinol
Tetrahydrocannabinol appears to be capable of both, having anxiolytic effect(s) and having anxiogenic effect(s).
Propofol
Propofol produces anxiolytic effect, beneficial during medical procedures requiring sedation.[34][35]
Racetams
Some racetam based drugs such as aniracetam can have an antianxiety effect.[36]
Herbal treatments
Certain natural substances are reputed to have anxiolytic properties, including the following:
- Garcinia indica (Kokum)[37]
- Scutellaria lateriflora[38]
- Coriandrum sativum (Coriander)[39]
- Salvia elegans (Pineapple Sage)[40]
- Cannabidiol (a cannabinoid found in marijuana)[41]
Supplements and over-the-counter pharmaceutical drugs
Picamilon is a prodrug formed by combining niacin with GABA that is able to cross the blood–brain barrier and is then hydrolyzed into GABA and niacin. It is theorized that the GABA released in this process activates GABA receptors, with potential to produce an anxiolytic response.[42][43] Picamilon is sold in the United States as a dietary supplement, while in Russia it is sold as a prescription drug.
Chlorpheniramine (Chlor-Trimeton)[44] and diphenhydramine (Benadryl) have hypnotic and sedative effects with mild anxiolytic-like properties (off-label use). These drugs are approved by the FDA for allergies, rhinitis, and urticaria.
Melatonin has anxiolytic properties, likely through interactions between GABAA and melatonin2 (MTNR1B) receptors activating the GABAergic system.[45][46] It has been used experimentally as an effective premedication for general anesthesia in surgical procedures, replacing the benzodiazepine midazolam.[46][47]
Inositol:[48] In a double-blind, controlled trial, myo-inositol (18 grams daily) was superior to fluvoxamine for decreasing the number of panic attacks and had fewer side-effects.[49]
Future drugs
Due to deficits with existing anxiolytics (either in terms of efficacy or side-effect profile), research into novel anxiolytics is active. Possible candidates for future drugs include:
- BNC210
- CL-218,872
- L-838,417
- SL-651,498
- S32212
- PH94B
Common drugs
Prescription-free drugs are often poor anxiolytics and often worsen the symptoms over time[citation needed]. However, they are often used for self-medication because of their wide availability (e.g. alcoholic beverages).
Alcohol
See also: Short-term effects of alcohol
Ethanol is used as an anxiolytic, sometimes by self-medication. fMRI can measure the anxiolytic effects of alcohol in the human brain.[50] The British National Formulary states, "Alcohol is a poor hypnotic because its diuretic action interferes with sleep during the latter part of the night." Alcohol is also known to induce alcohol-related sleep disorders.[51]
Inhalants
See also: Inhalant abuse § Patterns of non-medical usage, and Street children in Latin America § Drugs
The anxiolytic effects of solvents act as positive modulators of GABAA receptors (Bowen and colleagues 2006).[52]
Alternatives to medication
Psychotherapeutic treatment can be an effective alternative to medication.[53] Exposure therapy is the recommended treatment for phobic anxiety disorders. Cognitive behavioral therapy (CBT) has been found to be effective treatment for panic disorder, social anxiety disorder, generalized anxiety disorder, and obsessive-compulsive disorder. Healthcare providers can also help by educating sufferers about anxiety disorders and referring individuals to self-help resources.[54] CBT has been shown to be effective in the treatment of generalized anxiety disorder, and possibly more effective than pharmacological treatments in the long term.[55] Sometimes medication is combined with psychotherapy, but research has not found a benefit of combined pharmacotherapy and psychotherapy versus monotherapy.[56]
However, even with CBT being a viable treatment option, it can still be ineffective for many individuals. Both the Canadian and American medical associations then suggest the use of a strong but long lasting benzodiazepine such as clonazepam and alprazolam and an antidepressant, usually Prozac for its effectiveness.[57][unreliable source][original research?]
Note that adolescent anxiety once the patient becomes pubescent can often turn into depression, at which time other treatments may be required.[citation needed]
Transcendental Meditation technique shows marked efficacy in treating anxiety disorders says a meta-analysis of randomized controlled trials, "TM practice is more effective than treatment as usual and most alternative treatments, with greatest effects observed in individuals with high anxiety"[58] And a meta-analysis says: "Differential effects of relaxation techniques on trait anxiety: a meta-analysis. Effect sizes for the different treatments (e.g., Progressive Relaxation, EMG Biofeedback, various forms of meditation, etc.) were calculated. Most of the treatments produced similar effect sizes except that Transcendental Meditation had significantly larger effect size (p less than .005)"[59]
Regular practice of Transcendental Meditation enables some active duty service members battling post-traumatic stress disorder to reduce or even eliminate their psychotropic medication and get better control of their often-debilitating symptoms, researchers report in the journal Military Medicine.[60]
See also
- ATC code N05#N05B Anxiolytics
References
- ^ "antianxiety agent" at Dorland's Medical Dictionary
- ^ Youngstedt, Shawn D; Kripke, Daniel F (2007). "Does bright light have an anxiolytic effect? - an open trial". BMC Psychiatry 7: 62. doi:10.1186/1471-244X-7-62. PMC 2194679. PMID 17971237.
- ^ Peggy E. Hayes; et al. (September–October 1987). "Beta-blockers in anxiety disorders". Journal of Affective Disorders 13 (2): 119–130. doi:10.1016/0165-0327(87)90017-6.
- ^ "anxiolytic (tranquilizer)". Memidex (WordNet) Dictionary/Thesaurus. Retrieved 2010-12-02.
- ^ Galanter, Marc (1 July 2008). The American Psychiatric Publishing Textbook of Substance Abuse Treatment (American Psychiatric Press Textbook of Substance Abuse Treatment) (4 ed.). American Psychiatric Publishing, Inc. p. 197. ISBN 978-1-58562-276-4.
- ^ a b c Cassano, Giovanni B.; Rossi, Nicolò Baldini; Pini, Stefano (2002). "Psychopharmacology of anxiety disorders". Dialogues in Clinical Neuroscience 4 (3): 271–285. ISSN 1294-8322. PMC 3181684. PMID 22033867.
- ^ Gelder, M, Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp236.
- ^ Lader M, Tylee A, Donoghue J (2009). "Withdrawing benzodiazepines in primary care". CNS Drugs 23 (1): 19–34. doi:10.2165/0023210-200923010-00002. PMID 19062773.
- ^ Montenegro, Mariana; Veiga, Heloisa; Deslandes, Andréa; Cagy, Maurício; McDowell, Kaleb; Pompeu, Fernando; Piedade, Roberto; Ribeiro, Pedro (2005). "Neuromodulatory effects of caffeine and bromazepam on visual event-related potential (P300): A comparative study". Arquivos de Neuro-Psiquiatria 63 (2b): 410–5. doi:10.1590/S0004-282X2005000300009. PMID 16059590.
- ^ "Heroin addiction and anxiety disorder". DualDiagnosis. Retrieved 16 April 2016.
- ^ Liddell, Malcolm. "Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder". NCBI. Retrieved 16 April 2016.
- ^ Barlow, David H.; Durand, Mark V (2009). "Chapter 7: Mood Disorders and Suicide". Abnormal Psychology: An Integrative Approach (Fifth ed.). Belmont, CA: Wadsworth Cengage Learning. p. 239. ISBN 0-495-09556-7. OCLC 192055408.
- ^ John Vanin; James Helsley (19 June 2008). Anxiety Disorders: A Pocket Guide For Primary Care. Springer Science & Business Media. p. 189.
- ^ Jefferson, J. W. (1974). "Beta-adrenergic receptor blocking drugs in psychiatry". Archives of General Psychiatry 31 (5): 681. doi:10.1001/archpsyc.1974.01760170071012.
- ^ Noyes Jr, R (1982). "Beta-blocking drugs and anxiety". Psychosomatics 23 (2): 155–170. doi:10.1016/s0033-3182(82)73433-4.
- ^ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896131/
- ^ http://www.medscape.com/viewarticle/760070
- ^ http://www.ncbi.nlm.nih.gov/pubmed/7305609
- ^ "Adaptol. Summary of Product Characteristics" (PDF). Retrieved 24 July 2015.
- ^ Val'Dman, AV; Zaikonnikova, IV; Kozlovskaia, MM; Zimakova, IE (1980). "Characteristics of the psychotropic spectrum of action of mebicar". Biulleten' eksperimental'noi biologii i meditsiny 89 (5): 568–70. PMID 6104993.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information 26 (1): 63. 2012. Retrieved 21 March 2015.
- ^ Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). "Clinical study of the selective anxiolytic agent afobazol". Eksperimental'naia i klinicheskaia farmakologiia 64 (2): 15–9. PMID 11548440.
- ^ Silkina, IV; Gan'shina, TC; Seredin, SB; Mirzoian, RS (2005). "Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon". Eksperimental'naia i klinicheskaia farmakologiia 68 (1): 20–4. PMID 15786959.
- ^ Seredin, SB; Melkumian, DS; Val'dman, EA; Iarkova, MA; Seredina, TC; Voronin, MV; Lapitskaia, AS (2006). "Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction". Eksperimental'naia i klinicheskaia farmakologiia 69 (3): 3–6. PMID 16878488.
- ^ Antipova, TA; Sapozhnikova, DS; Bakhtina, LIu; Seredenin, SB (2009). "Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons". Eksperimental'naia i klinicheskaia farmakologiia 72 (1): 12–4. PMID 19334503.
- ^ Seredenin, SB; Antipova, TA; Voronin, MV; Kurchashova, SY; Kuimov, AN (2009). "Interaction of afobazole with sigma1-receptors". Bulletin of experimental biology and medicine 148 (1): 42–4. doi:10.1007/s10517-009-0624-x. PMID 19902093.
- ^ medicine net. "hydroxyzine (Vistaril, Atarax)". medicinenet.com. Archived from the original on 13 May 2008. Retrieved 17 May 2008.
- ^ Llorca PM, Spadone C, Sol O (November 2002). "Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study". J Clin Psychiatry 63 (11): 1020–7. doi:10.4088/JCP.v63n1112. PMID 12444816.
- ^ Bandelow, B.; Wedekind, D.; Leon, T. (Jul 2007). "Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention". Expert Rev Neurother 7 (7): 769–81. doi:10.1586/14737175.7.7.769. PMID 17610384.
- ^ Owen, RT. (Sep 2007). "Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety". Drugs Today (Barc) 43 (9): 601–10. doi:10.1358/dot.2007.43.9.1133188. PMID 17940637.
- ^ The Great Soviet Encyclopedia http://encyclopedia2.thefreedictionary.com/Validol[full citation needed]
- ^ Farmak Product Information - Validol http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf[full citation needed]
- ^ Itop Doctor http://doctor.itop.net/DirectoryItem.aspx?DirId=1&ItemId=268[full citation needed]
- ^ Banchs, Richard J.; Lerman, Jerrold (2014-03-01). "Preoperative anxiety management, emergence delirium, and postoperative behavior". Anesthesiology Clinics 32 (1): 1–23. doi:10.1016/j.anclin.2013.10.011. ISSN 1932-2275. PMID 24491647.
- ^ Vasileiou, Ioanna; Xanthos, Theodoros; Koudouna, Eleni; Perrea, Despoina; Klonaris, Chris; Katsargyris, Athanasios; Papadimitriou, Lila (2009-03-01). "Propofol: a review of its non-anaesthetic effects". European Journal of Pharmacology 605 (1-3): 1–8. doi:10.1016/j.ejphar.2009.01.007. ISSN 1879-0712. PMID 19248246.
- ^ Malykh AG; Sadaie MR (Feb 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767.
- ^ Patel, Manish; Antala, Bhavesh; Barua, Chandana; Lahkar, Mangala (2013). "Anxiolytic activity of aqueous extract of Garcinia indica in mice". International Journal of Green Pharmacy 7 (4): 332–35. doi:10.4103/0973-8258.122089.
- ^ Wolfson, P; Hoffmann, DL (2003). "An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers". Alternative therapies in health and medicine 9 (2): 74–8. PMID 12652886.
- ^ Emamghoreishi M, Khasaki M, Aazam MF (2005). "Coriandrum sativum: evaluation of its anxiolytic effect in the elevated plus-maze". Journal of Ethnopharmacology 96 (3): 365–370. doi:10.1016/j.jep.2004.06.022. PMID 15619553.
- ^ Herrera-Ruiz, Maribel; García-Beltrán, Yolanda; Mora, Sergio; Díaz-Véliz, Gabriela; Viana, Glauce S.B.; Tortoriello, Jaime; Ramírez, Guillermo (2006). "Antidepressant and anxiolytic effects of hydroalcoholic extract from Salvia elegans". Journal of Ethnopharmacology 107 (1): 53–8. doi:10.1016/j.jep.2006.02.003. PMID 16530995.
- ^ Zuardi, A.W.; Crippa, J.A.S.; Hallak, J.E.C.; Moreira, F.A.; Guimarães, F.S. (2006). "Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug". Brazilian Journal of Medical and Biological Research 39 (4): 421–9. doi:10.1590/S0100-879X2006000400001. PMID 16612464.
- ^ Shephard RA (June 1987). "Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action". Life Sci. 40 (25): 2429–36. doi:10.1016/0024-3205(87)90758-2. PMID 2884549.
- ^ Foster AC, Kemp JA (February 2006). "Glutamate- and GABA-based CNS therapeutics". Curr Opin Pharmacol 6 (1): 7–17. doi:10.1016/j.coph.2005.11.005. PMID 16377242.
- ^ Miyata, Shigeo; Hirano, Shoko; Ohsawa, Masahiro; Kamei, Junzo (2009). "Chlorpheniramine exerts anxiolytic-like effects and activates prefrontal 5-HT systems in mice". Psychopharmacology 213 (2–3): 441–52. doi:10.1007/s00213-009-1695-0. PMID 19823805.
- ^ Pierrefiche, G; Zerbib, R; Laborit, H (1993). "Anxiolytic activity of melatonin in mice: Involvement of benzodiazepine receptors". Research communications in chemical pathology and pharmacology 82 (2): 131–42. PMID 7905658.
- ^ a b Marseglia, Lucia; D’Angelo, Gabriella; Manti, Sara; Aversa, Salvatore; Arrigo, Teresa; Reiter, Russel J.; Gitto, Eloisa (2015). "Analgesic, Anxiolytic and Anaesthetic Effects of Melatonin: New Potential Uses in Pediatrics". International Journal of Molecular Sciences 16 (1): 1209–1220. doi:10.3390/ijms16011209. ISSN 1422-0067. PMC 4307299. PMID 25569095.
- ^ Naguib, Mohamed; Gottumukkala, Vijaya; Goldstein, Peter A. (2007). "Melatonin and anesthesia: A clinical perspective". Journal of Pineal Research 42 (1): 12–21. doi:10.1111/j.1600-079X.2006.00384.x. PMID 17198534.
- ^ Fux M, Levine J, Aviv A, Belmaker RH (1996). "Inositol treatment of obsessive-compulsive disorder". American Journal of Psychiatry 153 (9): 1219–1221. doi:10.1176/ajp.153.9.1219. PMID 8780431.
- ^ Palatnik A, Frolov K, Fux M, Benjamin J (2001). "Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder". Journal of Clinical Psychopharmacology 21 (3): 335–339. doi:10.1097/00004714-200106000-00014. PMID 11386498.
- ^ Gilman, J. M.; Ramchandani, V. A.; Davis, M. B.; Bjork, J. M.; Hommer, D. W. (2008). "Why We Like to Drink: A Functional Magnetic Resonance Imaging Study of the Rewarding and Anxiolytic Effects of Alcohol". Journal of Neuroscience 28 (18): 4583–91. doi:10.1523/JNEUROSCI.0086-08.2008. PMC 2730732. PMID 18448634.
- ^ http://pubs.niaaa.nih.gov/publications/aa41.htm[full citation needed]
- ^ Howard, Matthew O.; Bowen, Scott E.; Garland, Eric L.; Perron, Brian E.; Vaughn, Michael G. (2011). "Inhalant use and inhalant use disorders in the United States". Addiction science & clinical practice 6 (1): 18–31. PMC 3188822. PMID 22003419.
- ^ Zwanzger, P.; Deckert, J. (Mar 2007). "[Anxiety disorders. Causes, clinical picture and treatment]". Nervenarzt 78 (3): 349–59; quiz 360. doi:10.1007/s00115-006-2202-z. PMID 17279399.
- ^ Shearer, SL. (Sep 2007). "Recent advances in the understanding and treatment of anxiety disorders". Prim Care 34 (3): 475–504, v–vi. doi:10.1016/j.pop.2007.05.002. PMID 17868756.
- ^ Gould, RA; Otto, M; Pollack, M; Yap, L (1997). "Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis". Behavior Therapy 28 (2): 285–305. doi:10.1016/S0005-7894(97)80048-2.
- ^ Pull, CB. (Jan 2007). "Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders". Curr Opin Psychiatry 20 (1): 30–5. doi:10.1097/YCO.0b013e3280115e52. PMID 17143079.
- ^ CMA & AMA Home medical guides 2012 & 2014, along with personal experiences and WebMD reviews
- ^ David W. Orme-Johnson; Vernon A. Barnes (2014). "Effects of the Transcendental Meditation Technique on Trait Anxiety: A Meta-Analysis of Randomized Controlled Trials". THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE 20 (5): 330–341. doi:10.1089/acm.2013.0204.
- ^ Eppley K, et al. (1989). "Differential effects of relaxation techniques on trait anxiety: a meta-analysis". Journal of Clinical Psychology (45): 957–974.
- ^ PTSD Symptoms May Be Reduced With Transcendental Meditation - Neuroscience News January 11, 2016
Pharmacology: major drug groups
|
|
|---|---|
| Gastrointestinal tract/ metabolism (A) |
|
| Blood and blood forming organs (B) |
|
| Cardiovascular system (C) |
|
| Skin (D) |
|
| Genitourinary system (G) |
|
| Endocrine system (H) |
|
| Infections and infestations (J, P, QI) |
|
| Malignant disease (L01-L02) |
|
| Immune disease (L03-L04) |
|
| Muscles, bones, and joints (M) |
|
| Brain and nervous system (N) |
|
| Respiratory system (R) |
|
| Sensory organs (S) |
|
| Other ATC (V) |
|
Anxiolytics (N05B)
|
|
|---|---|
| 5-HT1A agonists |
|
| GABAAR PAMs |
|
| α2δ VDCC blockers |
|
| Antidepressants |
|
| Sympatholytics |
|
| Others |
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 鎮静剤および催眠剤の乱用および依存：薬理学および疫学 sedatives and hypnotics abuse and dependence pharmacology and epidemiology
- 2. 成人の広場恐怖症：疫学、臨床症状、診断 agoraphobia in adults epidemiology clinical manifestations and diagnosis
- 3. 周術期の投薬マネージメント perioperative medication management
- 4. 全身性エリテマトーデスの神経精神症状 neuropsychiatric manifestations of systemic lupus erythematosus
- 5. 授乳中の薬剤使用の原則 principles of medication use during lactation
English Journal
- Prevalence and implications of severe anxiety in a prospective cohort of acute chest pain patients.
- Schwarz J1, Prashad A, Winchester DE.
- Critical pathways in cardiology.Crit Pathw Cardiol.2015 Mar;14(1):44-7. doi: 10.1097/HPC.0000000000000038.
- Anxiety is a common condition which can manifest with symptoms of chest discomfort. Chest discomfort is one of the most common reasons to seek emergency medical care. We hypothesize that anxiety is highly prevalent, poorly diagnosed, and poorly treated in an acute care environment. We analyzed data
- PMID 25679088
- Psychiatrists' and primary care physicians' beliefs about overtreatment of depression and anxiety.
- Lawrence RE1, Rasinski KA, Yoon JD, Curlin FA.
- The Journal of nervous and mental disease.J Nerv Ment Dis.2015 Feb;203(2):120-5. doi: 10.1097/NMD.0000000000000247.
- Critics say that physicians overdiagnose and overtreat depression and anxiety. We surveyed 1504 primary care physicians (PCPs) and 512 psychiatrists, measuring beliefs about overtreatment of depression and anxiety and predictions of whether persons would benefit from taking medication, investing in
- PMID 25594787
- Ruthenium-catalyzed reductive amination without an external hydrogen source.
- Kolesnikov PN1, Yagafarov NZ, Usanov DL, Maleev VI, Chusov D.
- Organic letters.Org Lett.2015 Jan 16;17(2):173-5. doi: 10.1021/ol503595m. Epub 2014 Dec 31.
- A ruthenium-catalyzed reductive amination without an external hydrogen source has been developed using carbon monoxide as the reductant and ruthenium(III) chloride (0.008-2 mol %) as the catalyst. The method was applied to the synthesis of antianxiety agent ladasten.
- PMID 25549756
Japanese Journal
- 小児のデクスメデトミジン（DEX）の術中使用─利点と欠点─
- 虻川 有香子,広木 公一,尾崎 眞
- 日本臨床麻酔学会誌 35(1), 074-077, 2015
- デクスメデトミジン（DEX）は鎮静だけでなく鎮痛効果もあわせ持ち，投与量によって呼吸抑制を最小限に抑えられるなど他の鎮静薬にはない利点がある．現在小児領域においてDEXは欧米でも本邦においても適応外使用である．しかし集中治療領域では鎮静に広く用いられている．われわれの施設では，5～7歳のペクタスバー挿入術の患児にPCEAやIV-PCA投与下，DEXを投与し良好な鎮静効果を得ている．今後DEXの …
- NAID 130004892986
- ペインクリニシャンによる認知行動療法的な治療が有効であった慢性術後痛を呈したエチゾラム依存症の1症例
- 洪 淳憲,川端 真仁,大石 正隆,荒木 ひろみ,上野 由衣,河西 稔
- 日本ペインクリニック学会誌 20(1), 48-51, 2013
- ペインクリニシャンによる認知行動療法的な治療により，痛みが軽減し，多量の抗不安薬依存から離脱できた慢性術後痛の症例を報告する．症例は47歳，女性．5年前に胆石症にて胆のう摘出術を受け，以後腹部に痛みを生ずるようになった．痛みは持続的であり，時に発作的に増悪するため，他院ペインクリニック受診に加え，しばしば他院救急外来をも受診していた．当科受診時には抗不安薬であるエチゾラム（0.5 mg）を1日最高 …
- NAID 130005061955
- 「長崎大学病院オーラルペイン・リエゾン外来」におけるリエゾン診療の一例
- 岡安 一郎,鮎瀬 卓郎,和気 裕之
- 日本口腔顔面痛学会雑誌 6(1), 25-29, 2013
- 症例の概要：患者は27歳女性（主婦）．歯痛と歯の違和感を主訴に，2013年4月，「長崎大学病院オーラルペイン・リエゾン外来」を受診した．診察と検査の結果，口腔異常感症，顎関節症，知覚過敏と診断した．知覚過敏と顎関節症に対しては，それぞれ，保存治療とカウンセリングによる管理開始後，歯痛，筋痛ともに軽減した．しかし，その後，疼痛よりも違和感を強く自覚するようになった．心理社会面を中心とした医療面接と心 …
- NAID 130004953528
Related Links
- antianxiety / ˌæn ti æŋˈzaɪ ɪ ti, ˌæn taɪ-/ Show Spelled [an-tee-ang-zahy-i-tee, an-tahy-] Show IPA adjective tending to prevent or relieve anxiety. Origin: 1960–65; anti-+ anxiety Dictionary.com Unabridged Based on the Random ...
- antianxiety /an·ti·an·xi·e·ty/ (-ang-zi´ĕ-te) anxiolytic; reducing anxiety. an·ti·anx·i·e·ty (n t-ng-z-t, n t-) adj. Preventing or reducing anxiety. antianxiety [an″ti-ang-zi´ĕ-te] dispelling anxiety; called also anxiolytic. antianxiety agent a psychotropic ...
Related Pictures
★リンクテーブル★
| リンク元 | 「向精神薬」「anti-anxiety agent」「anxiolytic agent」「抗不安」 |
「向精神薬」
- 英
- psychotropic drug, psychotropic drugs, psychotropic agent, psychoactive drug, psychotropic, psychotropics
- 関
- 精神疾患
- 中枢神経系に作用して精神機能に影響を及ぼす薬物の総称
向精神薬に含まれる薬物
- 1. 抗精神病薬 antipsychotic drug <-メジャートランキライザー
- 2. 抗不安薬 antianxiety
- 3. 抗躁薬 antimanic
- 4. 抗うつ薬 antidepressant
-
「anti-anxiety agent」
「anxiolytic agent」
「抗不安」
- 英
- antianxiety
- 関
- 抗不安薬